Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.66 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside 
Via MarketBeat
Topics Artificial Intelligence
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
1 Mid-Cap Stock on Our Buy List and 2 We Avoid
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
Bristol Myers, Pfizer To Offer Blood Thinning Drug At Discount: Retail Chatter Around BMY Jump 60% In 24 Hours
Via Stocktwits
1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade
Via The Motley Fool
Topics Intellectual Property
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?
Via The Motley Fool
Topics Economy Intellectual Property
5 High-Yield Stock Picks to Add to Your Dividend Portfolio
It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth. 
Via The Motley Fool
2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 Right Now
Via The Motley Fool
Topics Retirement
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and nationwide delivery. 
Via Benzinga
Which S&P500 stocks are the most active on Thursday?
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Thursday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
1 Cash-Producing Stock with Competitive Advantages and 2 to Avoid
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback
Via The Motley Fool
Don’t Miss These 4 Stocks With Explosive Dividend Yields
Via MarketBeat
Topics Stocks
Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook
Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations. 
Via Benzinga
Topics Intellectual Property
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating. 
Via Benzinga
3 S&P 500 Stocks in Hot Water
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony
Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge. 
Via Benzinga
Topics Lawsuit
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
GSK Stock Gains As Flu Vaccine Rollout Begins And US Recovers From Most Severe Season In 15 Years
Fluarix and Flulaval are being shipped in single-dose, 0.5 mL pre-filled syringes and are not recommended for individuals with severe allergies to vaccine components or a history of Guillain-Barré... 
Via Stocktwits
Topics Death Lawsuit
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study
Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported. 
Via Benzinga
An Investor Wonders Why Trump's Tariffs Aren't Shaking The Markets. 'Does Wall Street Simply Not Care About The Economy Anymore?'
 
Via Benzinga
Topics Economy Government
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 vaccine patent dispute. 
Via Benzinga
Topics Intellectual Property
Should Politicians Be Allowed to Trade Stocks? The Big Debate
A growing chorus of lawmakers, ethics watchdogs, and concerned citizens are reigniting a high-stakes debate: Should U.S. politicians be allowed to buy and sell stocks while in office? Amidst rising... 
Via MarketMinute
Topics Artificial Intelligence Electric Vehicles
A Message to All Investors From Motley Fool CEO Tom Gardner
Via The Motley Fool
Topics Artificial Intelligence
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
From Pfizer Inc.
Via Business Wire
This Is the No. 1 Ultra-High-Yield Dividend Stock Held by Retail Investors on Robinhood -- and It's Not Even Close
The supercharged income stock coveted most by everyday investors is sporting a 5.14% yield. 
Via The Motley Fool
Topics ETFs
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.